ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Interventions: Drug: cytarabine
Drug: lenalidomide

First Posted Date: 2010-11-23

Last Posted Date: 2020-09-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 32

Registration Number: NCT01246622

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Effect of a Low Glycemic Index Diet on Breast Density

Not Applicable

Terminated

Conditions: Breast Cancer

Interventions: Behavioral: Low Glycemic Diet

First Posted Date: 2010-11-10

Last Posted Date: 2014-04-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 46

Registration Number: NCT01237938

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

Phase 1

Completed

Conditions: Barrett's Esophagus
CIS
HGD

Interventions: Drug: HPPH

First Posted Date: 2010-11-10

Last Posted Date: 2014-12-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01238042

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus

Phase 1

Completed

Conditions: CIS
Barrett's Esophagus
High Grade Dysplasia

Interventions: Drug: HPPH

First Posted Date: 2010-11-08

Last Posted Date: 2014-01-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01236443

Locations: 🇺🇸
Roswell Park cancer institute, Buffalo, New York, United States

Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia

Not Applicable

Completed

Conditions: Breast Cancer
Arthralgia

Interventions: Behavioral: Exercising block

First Posted Date: 2010-11-07

Last Posted Date: 2012-04-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 27

Registration Number: NCT01236417

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Brody Belt - Alternative Method of Securing a Patient's Urinary Drainage Bag

Not Applicable

Terminated

Conditions: Quality of Life

Interventions: Procedure: Quality of life

First Posted Date: 2010-10-27

Last Posted Date: 2017-12-08

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 12

Registration Number: NCT01228864

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Stage IV Rectal Cancer
Stage IV Colon Cancer

Interventions: Drug: leucovorin calcium
Biological: bevacizumab
Dietary Supplement: cholecalciferol
Drug: fluorouracil
Drug: oxaliplatin
Other: pharmacological study

First Posted Date: 2010-09-10

Last Posted Date: 2014-07-21

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 10

Registration Number: NCT01198548

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Stage IIIB Esophageal Adenocarcinoma
Stage IIIC Esophageal Squamous Cell Carcinoma
Stage IIIC Gastric Cancer
Stage IV Esophageal Adenocarcinoma
Stage IV Esophageal Squamous Cell Carcinoma
Undifferentiated Gastric Carcinoma
Adenocarcinoma of the Gastroesophageal Junction
Esophageal Undifferentiated Carcinoma
Gastric Adenocarcinoma
Recurrent Esophageal Adenocarcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Oxaliplatin
Drug: Pralatrexate

First Posted Date: 2010-08-10

Last Posted Date: 2017-12-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 35

Registration Number: NCT01178944

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Rochester General Hospital, Rochester, New York, United States

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Phase 1

Terminated

Conditions: Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer
Prostate Cancer

Interventions: Drug: vorinostat
Drug: temsirolimus
Other: laboratory biomarker analysis
Procedure: positron emission tomography/computed tomography

First Posted Date: 2010-08-03

Last Posted Date: 2022-10-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 13

Registration Number: NCT01174199

Locations: 🇺🇸
The Sydney Kimmel Comprehensive Center at John Hopkins, Baltimore, Maryland, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx

Phase 1

Completed

Conditions: Dysplasia
Carcinoma of the Oral Cavity
Carcinoma of the Oropharynx

Interventions: Drug: HPPH

First Posted Date: 2010-06-09

Last Posted Date: 2018-10-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 29

Registration Number: NCT01140178

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy